DynaLIFE Medical Labs, Edmonton, Alberta, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Dynacare, Brampton, Ontario, Canada.
Can J Cardiol. 2024 Jul;40(7):1183-1197. doi: 10.1016/j.cjca.2024.01.023. Epub 2024 Feb 8.
Detecting dyslipidemia early is important because atherosclerosis originates in childhood and early treatment can improve outcomes. In 2022, the Canadian Cardiovascular Society (CCS) and Canadian Pediatric Cardiology Association (CPCA) published a clinical practice update to detect, evaluate, and manage pediatric dyslipidemia. However, guidance on its translation into clinical laboratories is lacking. The Canadian Society of Clinical Chemists Working Group on Reference Interval Harmonization Lipid Team aims to assist guideline implementation and promote harmonized pediatric lipid reporting across Canada. The 2022 CCS/CPCA clinical practice update, 2011 National Heart, Lung, and Blood Institute integrated guidelines, and new data analysis (Canadian pediatric reference values from the Canadian Laboratory Initiative on Pediatric Reference Intervals [CALIPER] and retrospective patient data from large community laboratories) were incorporated to develop 5 key recommendations. These include recommendations to: (1) offer nonfasting and fasting lipid testing; (2) offer a lipid panel including total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglycerides, with apolipoprotein B and lipoprotein(a) available as individually orderable tests; (3) flag total cholesterol, LDL-C, and non-HDL-C results ≥ 95th percentile, and HDL-C results < 10th percentile, as recommended by CCS/CPCA/National Heart, Lung, and Blood Institute and validated by CALIPER, and flag apolipoprotein B and nonfasting triglyceride results ≥ 95th percentile on the basis of CALIPER, and do not flag Lp(a) results but mention the adult cutoff in the interpretive comments; (4) implement interpretive comments listed in the current report; and (5) implement the National Institutes of Health LDL-C equation. The Canadian Society of Clinical Chemists Working Group on Reference Interval Harmonization Lipid Team will support clinical laboratories to implement these recommendations using knowledge translation strategies. Harmonizing pediatric lipid reporting across Canadian clinical laboratories will optimize clinical decision-making and improve cardiovascular risk management in youth.
早期发现血脂异常很重要,因为动脉粥样硬化起源于儿童期,早期治疗可以改善预后。2022 年,加拿大心血管学会(CCS)和加拿大儿科心脏病学会(CPCA)发布了一项临床实践更新,以检测、评估和管理儿科血脂异常。然而,其在临床实验室中的翻译指导尚缺乏。加拿大临床化学学会参考区间协调脂质工作组旨在协助指南实施,并促进加拿大儿科脂质报告的协调统一。2022 年 CCS/CPCA 临床实践更新、2011 年美国国家心肺血液研究所综合指南以及新的数据分析(加拿大儿科参考值来自加拿大儿科参考区间实验室倡议 [CALIPER] 和大型社区实验室的回顾性患者数据)被纳入制定了 5 项关键建议。这些建议包括:(1)提供非空腹和空腹血脂检测;(2)提供包括总胆固醇、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、非高密度脂蛋白胆固醇和甘油三酯在内的血脂谱,载脂蛋白 B 和脂蛋白(a)可作为单独的可订购检测项目;(3)根据 CCS/CPCA/美国国家心肺血液研究所的建议和 CALIPER 的验证结果,标记总胆固醇、LDL-C 和非高密度脂蛋白胆固醇结果≥第 95 百分位数,HDL-C 结果<第 10 百分位数,并根据 CALIPER 标记载脂蛋白 B 和非空腹甘油三酯结果≥第 95 百分位数,但不标记脂蛋白(a)结果,而在解释性评论中提及成人切点;(4)实施本报告中列出的解释性评论;(5)实施美国国立卫生研究院 LDL-C 方程。加拿大临床化学学会参考区间协调脂质工作组将利用知识转化策略支持临床实验室实施这些建议。协调加拿大临床实验室儿科脂质报告将优化临床决策,并改善青少年的心血管风险管理。